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Abstract: Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL)
and natural killer (NK) cells, with cytolytic activity against microbes and tumors. Previous work
demonstrated the therapeutic effect of the intratumoral injection of recombinant granulysin and of
the systemic injection of an immunotoxin between granulysin and the anti-carcinoembryonic antigen
single-chain Fv antibody fragment MFE23, which were produced in the yeast Pichia pastoris. In the
present work, we developed a second immunotoxin combining granulysin and the anti-Tn antigen
single-chain Fv antibody fragment SM3, that could have a broader application in tumor treatment
than our previous immunotoxin. In addition, we optimized a method based on electroporation by
pulsed electric field (PEF) to extract the remaining intracellular protein from yeast, augmenting the
production and purificiation yield. The immunotoxin specifically recognized the Tn antigen on the
cell surface. We also compared the thermal stability and the cytotoxic potential of the extracellular
and intracellular immunotoxins on Tn-expressing human cell lines, showing that they were similar.
Moreover, the bioactivity of both immunotoxins against several Tn+ cell lines was higher than that of
granulysin alone.
Keywords: granulysin; scFv; immunotoxin; pulsed electric fields; Tn antigen; pancreatic tumors
1. Introduction
Granulysin is a protein contained in the granules of cytotoxic T lymphocytes (CTLs) and human
natural killer (NK) cells that possesses cytolytic potential on microbes and also on tumor cells [1–3].
Our group was the pioneer in the characterization of the molecular mechanism by which recombinant
granulysin induces the death of tumor cells [4,5], demonstrating that it fundamentally induces apoptosis
in various tumor cells of hematopoietic origin. Later on, we characterized this mechanism in more
detail, demonstrating that it was initiated by an increase in cytoplasmic Ca2+ concentration, followed
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by the generation of mitochondrial reactive oxygen species that initiated, in turn, the mitochondrial
apoptotic pathway, with caspase 3 activation and nuclear AIF translocation [4,6,7]. In these studies,
we also demonstrated that granulysin was able to kill cells from B-cell lymphocytic leukemia patients
while being nontoxic against lymphocytes from healthy donors [4]. Recently, we demonstrated the
great efficacy of recombinant granulysin in two in vivo tumor development models in nude mice,
mammary carcinoma MDA-MB-231 and multiple myeloma NCI-H929 [8]. We also demonstrated that
the antitumor action of granulysin was accompanied by a massive infiltration of NK cells in the tumor,
providing evidence of immunogenicity, as well as the absence of side effects [8].
In all these experimental approaches, recombinant granulysin was injected intratumorally when
the tumor was already detectable. However, considering a possible general clinical application of
this treatment, it would be desirable to perform systemic injections of the treatment and, if possible,
target granulysin specifically towards the tumor. With this objective, we generated an immunotoxin
between granulysin and the anti-carcinoembryonic antigen (CEA) single-chain fraction variable
(scFv) antibody fragment MFE23, one of the best approaches to achieve antitumor specificity [9].
We demonstrated that the immunotoxin targeted granulysin against the HeLa-CEA tumor after
systemic injection in nude mice xenotransplanted with this tumor. These experiments constitute the
proof of concept for the use of these immunotoxins in the systemic treatment of cancer [10].
However, the use of this immunotoxin would be limited to colon or gastric tumors because of the
pattern of expression of the CEA antigen. In the present work, we generated a new granulysin-based
immunotoxin directed against the Tn antigen. The Tn antigen is overexpressed in a high percentage
of tumors of diverse origin, and immunotoxins directed against it would have a broader application.
The Tn antigen is formed by a N-acetylgalactosamine (GalNAc) residue linked to either serine or
threonine residues by means of an alpha-O-glycosidic bond [11]. The SM3 antibody is capable of
recognizing the Tn antigen when it is part of a sequence of six amino acids present in the mucin MUC1.
Incomplete MUC1 glycosylation in tumor cells leads to the exposure of peptide epitopes, which are
masked in healthy cells. The crystal structure of the Tn-glycosylated MUC1 epitope recognized by the
antibody SM3 (A1PDT4(a-O-GalNAc)RP6) was characterized recently. Furthermore, glycosylation of
Thr produces around a three-fold enhancement in affinity relative to the naked peptide (APDTRP) [12].
In this context, we generated a new immunotoxin between the scFv fragment of SM3 and granulysin.
The SM3 immunotoxin was inserted into a plasmid suitable for production in the yeast Pichia pastoris,
and its production and purification were optimized in this yeast, which is frequently used in the
biotechnology industry to produce recombinant proteins and also certain natural products [13].
However, the amount of protein secreted by yeast to the supernatant was lower than in the case of the
other recombinant proteins, and we searched for methods to improve their recovery and purification yield.
Pulsed electric field (PEF) is a technique that consists in the application of an external electric
field in order to induce the electroporation of biological membranes. This effect can be reversible
or irreversible and leads to a rapid increment of membrane permeability, enabling the release of
intracellular biomolecules [14]. In contrast to other extraction techniques, the application of PEF does
not result in cell disintegration, minimizing the contamination of the extract with cell debris and
facilitating the subsequent purification of the target molecules [15].
In the present work, we used PEF technology to increase the production of the immunotoxin
formed by granulysin and the anti-Tn scFv SM3 (SM3GRNLY), comparing the binding to the Tn
antigen and the bioactivity on tumoral cell lines of SM3GRNLY obtained from yeast supernatant of
yeast submitted to PEF, that is, intracellular SM3GRNLY (iSM3GRNLY).
2. Results
2.1. Design of Plasmids for the Production of Recombinant SM3-Granulysin Immunotoxin
The construct coding for the 9 kDa granulysin (GRNLY) gene alone was described in our previous
work [10]. We designed a construct that will encode for an immunotoxin formed by granulysin bound
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through a flexible linker of 21 amino acids (formed by Ser and Gly residues) to the anti-Tn scFv
SM3 (Figure 1). Both constructs included a tag of six histidines to facilitate subsequent detection and
purification. The corresponding plasmids were amplificated in Escherichia coli and isolated. Plasmids were
then linearized with SacI and purified. Then, plasmids were transfected by electroporation in Pichia pastoris
and the transfected colonies selected, as indicated in our previous work [10].
Figure 1. Schematic representations of granulysin (GRNLY) and of the immunotoxin between granulysin
and the anti-Tn scFv SM3 (SM3GRNLY). The α-Factor signal peptide is used to direct secretion of the
recombinant proteins in Pichia pastoris, and the 6xHis tag is appended for immunodetection and affinity
purification, respectively.
2.2. Production and Purification of the Recombinant Proteins in Pichia Pastoris. Obtention of the Intracellular
Protein by Pulsed Electric Field Technology
Subsequently, GRNLY and SM3-GRNLY were subcloned into the pPICZalphaA vector for
production in yeast cells. Both constructs were secreted to the P. pastoris supernatant, as demonstrated
by Western blot (data not shown). For purification, the extracellular medium of P. pastoris cells was
collected after 72 h of methanol induction. This time was previously optimized with other recombinan
proteins (see [10] and references thereoff), and, in the case of SM3GRNLY, an increase in the time of
induction until 96 h or a reduction to 24 or 48 h did not improve the yield of production. Both GRNLY
and SM3GRNLY were purified by immobilized metal affinity chromatography, with good yield for
GRNLY, around 5 mg/L in the different batches, but with a lower yield for SM3GRNLY, around 2 mg/L.
Taking into account the difference in molecular weight, this difference in weight yield meant a difference
of 10-fold in molar yield (see Supplementary Table S1). Purified GRNLY exhibited a doublet beween 11
and 12 kDa, in agreement with its predicted molecular weight, taking into account the His-tag and the
glycans contribution (see the Coomassie staining of different fractions of purification in Supplementary
Figure S1A and the immunoblot analysis of different purified batches using anti-His-tag antibody
in Supplementary Figure S1B). Recombinant GRNLY secreted by Pichia pastoris has been previously
shown to be O-glycosylated [16].
On the other hand, SM3GRNLY migrated at a molecular weight around 47 kDa, slightly higher
than that calculated from the addition of those of GRNLY and SM3 (see the Coomassie staining
of different steps of purification in Supplementary Figure S1C and the immunoblot analysis using
anti-His-tag antibody in Supplementary Figure S1D).
In our previous studies, we demonstrated that granulysin was stable at 4 ◦C in PBS for at least
three months [8,10], and, here, we tested SM3GRNLY stability and conservation. We observed that
the immunotoxin lost half of its cytotoxic potential against Jurkat cells after one week of storage at
4 ◦C. Hence, we tested different usual protocols of protein conservation and found that freezing in the
presence of glycerol and use immediately after thawing maintained protein bioactivity for months.
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However, the amount of glycerol used needed to be optimized to avoid toxicity. Although protein
stability was guaranteed in the presence of glycerol amounts from 5 to 0.5%, glycerol was toxic by
itself in concentrations higher than 1% (see Supplementary Figure S2). Hence, proteins were stored
frozen in the presence of 1% glycerol.
The low yield of immunotoxin production precluded the performance of adequate pre-clinical
studies or its future clinical application. This is why we intended the use of pulsed electric fields
to improve the yield of production from yeast. The extraction of the immunotoxin that remains in
the cytoplasm of the P. pastoris cells requires the irreversible electroporation of the cell membrane.
As it is well known that irreversible electroporation of cells leads to their inactivation, the number of
inactivated cells after the application of PEF was used as an index to estimate treatment conditions
required to electroporate the P. pastoris cells [17]. The inactivation along the time of P. pastoris after
exposure to PEF treatments of varying electric field strengths is shown in the left panel of Figure 2.
While the treatment applied at 8 kV/cm was ineffective, inactivation was increased with a treatment
duration under electric fields of 12 kV/cm or higher. According to these results, the treatment conditions
selected to evaluate the release of proteins from P. pastoris after electroporation were 12, 16 and 20 kV/cm
during 150 µs, corresponding to 84, 90 and 99% of cells inactivated, respectively. Protein release from
untreated and PEF-treated cells at different electric field intensities is shown in the right panel of
Figure 2. While protein release was not observed in untreated cells, when the cells of P. pastoris were
previously treated with PEF, the concentration of protein in the medium in which yeast was suspended
increased with time. Protein release from the PEF-treated cells increased with the intensity of the
applied electric field strength. After 180 min of extraction, the protein concentration in the medium of
the P. pastoris cells treated at 20 kV/cm was 377 mg/L. This concentration is 3.77 or 1.23 times higher
than when the cells were treated at 12 and 16 kV/cm, respectively. According to these results, a PEF
treatment of 20 kV/cm for 150 µs and a subsequent extraction period of 180 min were selected for
extracting the intracellular SM3GRNLY.
Figure 2. Optimization of intracellular SM3GRNLY (iSM3GRNLY) production from P. pastoris. Left panel:
inactivation of Pichia pastoris by pulsed electric field (PEF) treatment of different electric field strengths.
Treatment of 8 kV/cm (•), 12 kV/cm (H), 16 kV/cm (), 20 kV/cm (N). Right panel: effect of different
electric field strengths in intracellular protein extraction. Treatment of 12 kV/cm (), 16 kV/cm (N),
20 kV/cm (H) and control (•).
As shown in Figure 3, the molecular weight of the purified intracellular protein was very similar
to that of secreted SM3GRNLY. In the case of iSM3GRNLY, some degree of protein fragmentation can
be observed depending on the batches. However, the 47 kDa band always represented at least a 90% of
the total final protein, as quantified by the Image J densitometric program. iSM3GRNLY was stored
frozen in the presence of 1% glycerol, as optimized previously with SM3GRNLY (see above).
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Figure 3. Coomassie staining (left panel) and anti-His tag immunoblot (right panel) of representative
purified batches of SM3GRNLY, iSM3GRNLY or GRNLY, as indicated.
Hence, we produced SM3GRNLY from yeast supernatant, and we submitted the remaining living
yeast to the optimized pulse electric field protocol, recovered the cellular content and purified in
this way the SM3GRNLY that had not been secreted previously by yeast (intracellular SM3GRNLY
or iSM3GRNLY). An illustration of a representative purification process of iSM3GRNLY is shown
in Supplementary Figure S3. Intracellular SM3GRNLY accounted for more than 8 mg per liter of
yeast medium, that is, four-fold the protein that was secreted to the supernatant (see Supplementary
Table S1). This result indicates that most of the protein was still intracellular (around 80%, depending
on the batches).
2.3. Assays of Thermal Denaturation
We performed the comparison of the thermal stability of both proteins by differential scanning
fluorimetry using Sypro orange dye. As shown in Figure 4, the thermal denaturation curves of
SM3GRNLY and iSM3GRNLY were similar, and the melting temperature (Tm) was of 58.4 ◦C and
50 ◦C, respectively. This demonstrates that the protein isolated from yeast supernatant was more stable
than the protein extracted from yeast using PEF technology, but that both proteins were reasonably
stable in the physiological range of temperatures.
Figure 4. Thermal stability of immunotoxins. SM3GRNLY and iSM3GRNLY stability was tested by
differential scanning fluorimetry using Sypro orange dye in the indicated temperature range at pH 7.
Triplicate curves are shown and the calculated average temperature (Tm) indicated in each case.
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2.4. Immunotoxin Binding to the Tn Antigen Expressed on the Cell Surface
To determine whether the immunotoxin could bind its antigen on the cell surface, we performed
flow cytometry on several tumoral cell lines, as described in our previous study [10]. As shown in
Figure 5A, SM3GRNLY (upper panels) and iSM3GRNLY (lower panels) did not substantially bind
to A549 lung adenocarcinoma cells or mammary adenocarcinoma MCF7—at least no more than the
control reagents. However, SM3GRNLY gave a good Tn labeling on the surface of the two pancreatic
adenocarcinoma cells Panc-1 and CAPAN-2, the multiple myeloma cells NCI-H929 and the T cell
leukemia Jurkat (Figure 5B), indicating that these tumor cells expressed a high amount of the Tn
antigen on their surface and that the SM3 scFv bound to it with high affinity. Of note, we could also
demonstrate binding of iSM3GRNLY to the Tn antigen expressed on the surface of Panc-1, Capan-2,
H929 and Jurkat cells, albeit at a lower level than SM3GRNLY in the last two cell lines (Figure 5B).
Figure 5. SM3GRNLY and iSM3GRNLY binding to the Tn antigen expressed on the cell surface.
(A). MCF7 (left panels) and A549 (right panels) were stained with SM3GRNLY (upper panels) or
iSM3GRNLY (lower panels), as indicated in Materials and Methods, and labellings analyzed by
flow cytometry. Panc-1, Capan-2, NCI-H929 and Jurkat cells were stained with SM3GRNLY or with
iSM3GRNLY (B), as indicated. Black histograms correspond to the fluorescence of the specific labellings
and gray histograms to that of the negative controls.
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2.5. In Vitro Cytotoxic Effect of GRNLY, SM3GRNLY and iSM3GRNLY
Next, we addressed if the immunotoxin could promote preferential killing of tumor target cells
depending on their level of expression of the Tn antigen or, rather, on the effective binding of SM3GRNLY
to their surface. As shown in Figure 6A, the cytotoxicity of SM3GRNLY was the same as that of GRNLY
alone on A549 and MCF-7 cells, that is, cell lines that did not show a substantial binding of SM3GRNLY
in the flow cytometry experiments shown in Figure 5A. However, the SM3GRNLY immunotoxin
exhibited a higher cytotoxicity than granulysin alone on H929 multiple myeloma cells, reducing the
IC50 from 10 to 2.5 µM (Figure 6B, lower panel). At 10 µM, the percentage of apoptotic cells treated
with the immunotoxin was twice that of H929 cells treated with granulysin (90% vs. 45%, respectively).
We also demonstrated the enhanced cytotoxicity of the immunotoxin compared with granulysin alone
on the pancreatic carcinoma Capan-2 cells, showing that 10 µM of SM3GRNLY induced 70% of cell
death, while GRNLY did not induce more than 45% (Figure 6B, left upper panel). Finally, in Panc-1
pancreatic cells, SM3GRNLY showed higher cytotoxicity than GRNLY at low concentrations, but this
difference was no longer observed at 10 µM (Figure 6B, right upper panel). Of note, H929, Capan-2
and Panc-1 cells showed a positive labeling when using SM3GRNLY for the flow cytometry analysis
shown in Figure 5.
Figure 6. Cytotoxicity of GRNLY and SM3GRNLY on tumoral cell lines. (A) A549 or MCF7 cells
were incubated with increasing concentrations of recombinant GRNLY, SM3GRNLY or iSM3GRNLY,
as indicated, for 24 h. (B), NCI-H929, Capan-2 or Panc-1 cells were incubated with increasing concentrations
of recombinant GRNLY, SM3GRNLY or iSM3GRNLY, as indicated, for 24 h. Apoptotic cell death was
determined in all cases by detection of phosphatidylserine exposure by staining with Annexin-V conjugated
with fluorescein isothiocyanate (FITC) and flow cytometry. Basal labelling of cells treated with PBS is
also shown as control (black bars). Results are the mean ± SD of at least three different experiments.
**, p < 0.01; ***, p < 0.001.
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Regarding iSM3GRNLY, we could demonstrate that its cytotoxicity against H929 and Capan-2
cells was similar to that of SM3GRNLY, showing that it was as bioactive as the secreted protein
(Figure 6B, light grey bars). In the case of Panc-1, a cell line especially refractory to granulysin toxicity,
iSM3GRNLY behaved similarly to GRNLY at all concentrations tested, showing 50% of toxicity at
10 µM concentration.
3. Discussion
Our previous studies demonstrate the antitumoral efficiency of recombinant granulysin [4,8].
In addition, we also demonstrated that a chimeric construction composed of granulysin and an anti-CEA
scFv maintained, on one hand, its binding to the CEA antigen and, on the other, its bioactivity against
tumors [10]. This chimeric immunotoxin was even more cytotoxic against cells that expressed the CEA
antigen, demonstrating also its targeting potential, especially in vivo [10]. However, the usefulness of
this immunotoxin would be limited to colon or gastric tumors due to the specific pattern of expression
of the CEA antigen. We have generated here a new granulysin-based immunotoxin directed against the
Tn antigen, which in principle, would have a broader application, since the Tn antigen is overexpressed
in a large variety of tumors of diverse origin [11]. In fact, MUC1-associated Tn is one of the first
antigens expressed in solid tumors chosen to develop chimeric antigen receptor (CAR) T cells [18,19].
We chose the yeast P. pastoris for the production of GRNLY and the immunotoxins because of their
high yield of production of folded proteins, disulfide bond formation as well as glycosylation in the
absence of endotoxins, frequently associated with recombinant proteins produced in bacteria [20,21].
However, the yield of recombinant SM3GRNLY production in P. pastoris was somewhat low. This is why
we decided to use pulsed electric field (PEF) technology, a technique that induces the electroporation
of biological membranes and the release of intracellular biomolecules [14,22]. In contrast with other
extraction techniques, PEF technology does not result in cell disintegration, and in the case of proteins,
it does not induce their denaturation [23,24]. The use of PEF for efficient and selective recovery of
recombinant proteins such as human ferritin heavy chain (FTH1) or LYTAG-β-galactosidase expressed
intracellularly in the yeasts Hansenula polymorpha and Saccharomyces cerevisiae has been previously
reported [23,24]. In these studies, in which electric fields lower than 10 kV/cm and pulsed in the
range of milliseconds were used, the subsequent incubation of the permeabilized cells with lyticase
was required to obtain high extraction yields. In our case, the use of higher electric fields allowed
us to obtain a high efficiency of extraction (4-fold increase) without requiring a following enzymatic
treatment, confirming that the technique has a lot of possibilities in the protein biotechnology field.
We first demonstrated that the immunotoxin obtained from yeast supernatant by conventional
methods retained its specific binding to the Tn antigen expressed on the surface of different human
tumor cell lines. Interestingly, we detected almost no binding of SM3GRNLY to the lung tumor A549 or
to the mammary tumor MCF7, although it has been suggested that these cell lines express the MUC-1
Tn antigen. However, in both cases, it was observed that several subpopulations existed with different
levels of Tn expression [25,26], and, probably, the level of Tn expression in these cell lines is lower than
that in the rest of the cells analyzed. A substantial binding of SM3GRNLY was detected in the acute
T cell leukemia Jurkat, in the multiple myeloma NCI-H929, and in the two pancreatic adenocarcinomas
Panc-1 and Capan-2. Moreover, the immunotoxin clearly increased granulysin cytotoxicity against
these last cell lines, while the cytotoxicity on A549 or MCF7 cells was the same as that observed to
granulysin alone. These results suggest that an increased binding of the immunotoxin to Tn expressed
on the cell surface correlates with a higher cytotoxicity, and they suggest a positive targeting of the
tumoral antigen by the antibody moiety.
Regarding the intracellular protein obtained by PEF technology, we have also shown that it binds
to the Tn antigen expressed on the cell surface and, more importantly, that it maintains its cytotoxic
bioactivity. iSM3GRNLY showed again a higher cytotoxicity than GRNLY alone, at least on H929 and
Capan-2 cells, that was around the same as that of the immunotoxin obtained from yeast supernatant.
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Immunotoxins normally combine a bacterial or plant toxin with full-length IgG or to scFv
antibody fragments. For example, the recently approved moxetumomab pasudotox combine the
PE38 Pseudomonas endotoxin with and anti-CD22 scFv, and it is suitable for the treatment of hairy
cell leukemia [27]. However, the immune reaction against the toxin moiety in patients may reduce
their clinical success [28,29]. In this respect, the granulysin-based immunotoxins described here or in
our previous work [10] are devoid of immunogenicity, since granulysin is a physiologically normal
human protein.
In summary, on one hand, the use of PEF technology to obtain the recombinant anti-Tn SM3GRNLY
immunotoxin substantially increased its production yield, clearing the way for its future production
escalation in biotech companies. On the other hand, the confirmation of the increased cytotoxicity of
granulysin-based immunotoxins on tumoral cells that express the targeted antigen, together with their
lack of immunogenicity, makes them good candidates as new anti-tumoral agents.
4. Materials and Methods
4.1. Cell Culture
Human tumor cell lines were cultured at 37 ◦C and 5% CO2 using standard procedures. The acute
T cell leukemia Jurkat and the multiple myeloma cells line NCI-H929 were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS) (Pan Biotech, Aidenbach, Germany).
The mammary adenocarcinoma MCF7, the non-small cell lung cancer A549 and the pancreatic
adenocarcinoma cell lines Panc-1 and Capan-2 cultured in DMEM medium (Pan Biotech GmbH)
supplemented with 10% FBS (Sigma, Madrid, Spain). Culture media were supplemented with
penicillin/streptomycin (Pan Biotech) and GlutaMAX (Invitrogen, Barcelona, Spain), and the absence
of mycoplasma was routinely tested by PCR.
4.2. Bacterial Strains, Plasmids, and Culture Conditions
The E. coli DH5α strain was grown at 37 ◦C in Luria-Bertani medium (LB; Oxoid, Basingstoke, UK).
Pichia pastoris was grown at 30 ◦C in yeast extract with peptone and dextrose (YPD) broth (Formedium)
for routine maintenance and in buffered glycerol-complex medium (BMGY) (1% yeast extract,
2% peptone, 1.34% yeast nitrogen base (YNB) 1% glycerol, 400 µg/L biotin, and 0.1 M potassium
phosphate, pH 6.0) for expansion and big-scale production, followed by cultured at 18 ◦C in buffered
methanol-complex medium (BMMY ) (1% yeast extract, 2% peptone, 1.34% YNB, 1% methanol, 400 µg/L
biotin, and 0.1 M potassium phosphate, pH 6.0) for induction of the recombinant protein. The synthetic
gene encoding 6xHis-tagged 9 kDa granulysin was synthesized and inserted in the pPICZαA plasmid
as indicated in Ibáñez 2019. The synthetic gene coding for 6xHis-tagged SM3GRNLY was synthesized
and inserted in the pPICZαA plasmid by Genscript (Leiden, The Netherlands). Both plasmids were
amplificated in E.coli and isolated by NucleoSpin® Plasmid EasyPure (Macherey-Nagel). Plasmids were
linearized with SacI (Takara) and purified by Ilustra™ GFX™ PCR DNA and Gel Band Purification
kit (GE Healthcare). The transformation of P. pastoris and the selection of transfected colonies was
performed by the methods described in Wiedner 2010 and Ibáñez 2019.
4.3. Expression and Purification of Extracellular Recombinant Granulysin and SM3-Granulysin Immunotoxin
in Pichia Pastoris
The preinoculum of P. pastoris cell strains X33 for SM3GRNLY and SMD1168 for GRNLY,
was cultured in 100 mL YPD medium overnight at 30 ◦C for activation; the cells were then added
to 1000 mL of BMGY medium, incubated overnight at 30 ◦C for growth and finally overnight in
BMMY medium at 18 ◦C for induction. All these culture steps were performed in a thermostated
shaking incubator at 250 rpm as shaking intensity. The culture was fed with 1% methanol every
24 h for 2 or 3 days; then, supernatants were concentrated using Pellicon® XL Ultracel 0.005 m2
cassettes (MerckMillipore, Burlington, MA, USA), dialyzed in PBS and proteins purified by Ni2+
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affinity chromatography (Ni-NTA agarose, Qiagen, Madrid, Spain), with an elution buffer containing
20 mM imidazole, 300 mM NaCl and 20 mM Tris-HCl, pH 8. Eventually, the eluate was concentrated
and its buffer was changed to PBS using Amicon® filters (MerckMillipore).
4.4. Expression and Purification of Intracellular Recombinant SM3-Granulysin Immunotoxin from Pichia
Pastoris by Pulsed Electric Field Technology
The PEF equipment used in this work was the commercial model EPULSUS®-PM1-10 (Energy
Pulse System, Lisbon, Portugal). P. pastoris cells were resuspended in McIlvaine buffer (pH 7.0 and
1.50 mS/cm) at a concentration of around 108 cells/mL and PEF-treated in continuous flow (5.0 L/h) in
parallel electrode chamber of 3.0 cm length, 0.50 cm width and a gap of 0.40 cm. The calculated mean
residence time in the treatment chamber was 0.40 s. A heat exchanger consisting of a coil submerged
in a thermostatic batch was used to set the initial temperature of the yeast before the treatment at 10 ◦C.
The temperature of the yeast suspension after the PEF treatment chamber never exceeded 30 ◦C.
P. pastoris cells were PEF treated at electric fields strength between 8 and 20 kV/cm for treatment
times between 15 and 180 µs. After the treatments, serial decimal dilutions were poured plated in
potato dextrose agar in order to monitor P. pastoris cell inactivation. The number of viable cells was
expressed in colony-forming units (CFU), corresponding to the number of colonies counted after 48 h
of incubation at 25 ◦C. Inactivation data were expressed as the ratio between the initial number of
survivors (No) and the number of survivors after different treatment times (Nt).
Release of protein from untreated and PEF-treated (12, 16 and 20 kV/cm for 15 to 180 µs) cells of
P. pastoris was monitored after 180 min of incubation at 20 ◦C in a McIlvaine buffer solution of pH 7 and
1 mS/cm of conductivity. Quantitative analysis of released proteins was conducted by the microplate
procedure of Pierce™ BCA Protein Assay Kit (Thermo Scientific, Rockford, IL 61105, USA).
4.5. Protein Stability Determinations
Thermal stability tests were performed with the differential scanning fluorimetry technique also
known as thermal displacement test (thermofluor). The experiment was performed on a 96-well
plate in the Stratagene Mx3005P (Agilent Technologies, Waldbronn, Germany). In a final reaction
volume of 40 µL, the proteins, at a final concentration of 0.5 mg/mL, were incubated in the presence of
Sypro orange (Invitrogen) at a final 5-fold concentration, following the manufacturer’s instructions.
The reaction was performed in 75 cycles of 60 s each, with an initial temperature of 25 ◦C and an increase
of 1 ◦C per cycle. The emitted fluorescence was captured in each cycle and was plotted on Graphpad
prism. To obtain the Tm, the curve data were fitted to the Boltzmann equation. Determinations were
performed in 25 mM HEPES pH 7.0.
4.6. Flow Cytometry Analysis of Binding of SM3GRNLY or iSM3GRNLY to the Tn Antigen
To analyze binding to the Tn antigen on the surface of living cells, 105 cells per well were placed in
a 96-well round-bottom plate. Cells were first incubated with SM3GRNLY or iSM3GRNLY at 10 µg/mL
in PBS with 5% FBS for 30 min at 4 ◦C followed by mouse anti-histidine tag antibody (1:200; Genscript,
Leiden, The Netherlands) and goat anti-mouse antibody bound to FITC (1:200; Caltag, Barcelona, Spain).
After each incubation, cells were washed with 5% FBS in PBS. The binding was determined on the
surface of cells using a FACScalibur flow cytometer (BD Biosciences). Control negative labellings were
also established by making the same incubations indicated above, but in the absence of SM3GRNLY
or iSM3GRNLY.
4.7. Cytotoxicity Assays
Cells were seeded in complete medium at 1 × 106 cells/mL in 50 µL per well in 96 well plates,
and GRNLY, SM3GRNLY or iSM3GRNLY were added at the indicated concentrations. In control wells,
the same volume of PBS was added in each case. Cells were incubated for 24 h at 37 ◦C and cell death
was analyzed by analyzing PS exposure by flow cytometry using Annexin-V-FITC (BD Biosciences,
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Madrid. Spain). For this, and after the incubation period, cells were washed with PBS and incubated
with Annexin-V-FITC in annexin-binding buffer (140 mM NaCl, 2.5 mM CaCl2,10 mM Hepes/NaOH,
pH 7.4) for 15 min and analyzed by flow cytometry.
4.8. Statistical Analysis
Statistical significance was evaluated by using Student t-test for non-paired variants. Differences were
considered significant if p < 0.05.
5. Patents
The use of granulysin immunotoxins as an anti-tumoral treatment is protected by the patent
application PCT/ES2018/P201830768 presented to the Spanish Bureau of Patents and Brands (OEPM)
on 07/26/2018, extended to international application with the World Intellectual Property Organization
(WIPO) publication number WO/2020/020978 on 01/30/2020.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/17/6165/s1.
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